B2M and neoplasm: Genetic changes, such as homozygous or biallelic gene loss for B2M, lead not only to decreased HLA class I expression on tumour cells, but also increased resistance to immune checkpoint receptors targeting immunotherapy, e.g., anti-PD-1 and anti-CTLA-4 treatment [362,363].